Also, Mayne is essentially a generic medicine formulator/developer/manufacturer with a $1.2b market cap. In order to purchase Teva's generic products its doing a $888m cap. raising. Even if Teva could assign its rights to a third party, its hard to see why either Mayne or MSB would have any interest in such a proposal. MBS is looking for deep pockets and established avenues for CHF commercialization, while Mayne is trying to build a global generics business. As with Teva and MSB, Mayne & MSB are heading in very different directions.
Mayne Pharma, page-10
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71720 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 10463 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |